Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

(2019) David Fitchett et al.   CIRCULATION

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

(2019) Eri T. Kato et al.   CIRCULATION

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events

(2019) Milton Packer   CIRCULATION

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

(2018) Karin Rådholm et al.   CIRCULATION

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function

(2018) Isabelle Johansson et al.   Diabetes & Vascular Disease Research

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014

(2017) Karolina Szummer et al.   EUROPEAN HEART JOURNAL

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

(2017) Aidin Rawshani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project

(2017) Suzanne V Arnold et al.   European Journal of Preventive Cardiology

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013

(2016) Anna Norhammar et al.   DIABETOLOGIA

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure

(2016) Isabelle Johansson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: Results From the Swedish Coronary Angiography and Angioplasty Registry

(2015) V. Ritsinger et al.   Circulation-Cardiovascular Interventions

Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes

(2015) Petar M. Seferović et al.   EUROPEAN HEART JOURNAL

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort

(2014) Viveca Ritsinger et al.   Diabetes & Vascular Disease Research

Molecular mechanisms of diabetic cardiomyopathy

(2014) Heiko Bugger et al.   DIABETOLOGIA

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

(2014) John J V McMurray et al.   Lancet Diabetes & Endocrinology

External review and validation of the Swedish national inpatient register

(2011) Jonas F Ludvigsson et al.   BMC PUBLIC HEALTH